Mohamed Altai
1 – 10 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
The influence of domain permutations of an albumin-binding domain-fused her2-targeting affibody-based drug conjugate on tumor cell proliferation and therapy efficacy
(
- Contribution to journal › Article
-
Mark
PSA-Targeted Alpha-, Beta-, and Positron-emitting immunotheranostics in murine prostate cancer models and nonhuman primates
(
- Contribution to journal › Article
-
Mark
A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen
(
- Contribution to journal › Article
- 2020
-
Mark
HER2-specific pseudomonas exotoxin a pe25 based fusions : Influence of targeting domain on target binding, toxicity, and in vivo biodistribution
(
- Contribution to journal › Article
-
Mark
Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules
(
- Contribution to journal › Article
-
Mark
Evaluating the therapeutic efficacy of mono-and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model
(
- Contribution to journal › Article
-
Mark
Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting
(
- Contribution to journal › Article
- 2015
-
Mark
Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
(
- Contribution to journal › Article
- 2014
-
Mark
Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re
(
- Contribution to journal › Article
-
Mark
Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule
(
- Contribution to journal › Article